NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
4 trialsNCT00411749 2017-04-21
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00496626 2017-04-17
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00551187 2015-06-08
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed